Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
UK Startups and Innovation
22OCT

Orbital's $50m raise has no UK lead

4 min read
16:30UTC

Orbital Industries closed a $50m Series B on 28 May led by Europe's Plural with NVIDIA's NVentures; not one pound came from a UK fund. The talent is British, the growth equity is not.

TechnologyDeveloping
Key takeaway

Britain builds the deeptech founders but funds none of their Series B rounds at home.

Orbital Industries closed a $50m Series B on Thursday 28 May, led by London-based Plural with Nvidia's venture arm NVentures entering for the first time, alongside a multi-year product partnership with Amazon Web Services (AWS), Amazon's cloud division⁠1. The founders include Jonathan Godwin, who spent five years at DeepMind, the London AI lab, working on artificial intelligence for materials science. Orbital sells cheaper, cooler compute: a PFAS-free (per- and polyfluoroalkyl substances, the 'forever chemicals') dielectric cooling fluid and modular data centres deployable in six months rather than three years, built on an atomic-simulation engine that models 100,000 atoms on a single graphics processing unit (GPU), ten times faster than the nearest alternative⁠2.

The round is the third time in 18 months a London company founded by ex-DeepMind researchers has landed a major raise, after Isomorphic Labs' $2.1bn Series B and Ineffable Intelligence's $1.1bn seed. DeepMind now functions as Britain's primary deeptech founder factory. The capital stack does not keep pace: Plural is European, while NVentures, Radical Ventures and Compound are American, so not one pound of the $50m came from a UK-domiciled fund or sovereign vehicle. Britain grew the talent and seeded the idea; the growth-stage equity, and the upside that compounds on it, sits abroad.

The product answers a constraint visible since April, when London's data-centre grid hit saturation and AI Growth Zones began pushing capacity north toward Scotland. Orbital's selling point is a way around that wall: modular sites that drop in fast and run hot without toxic coolant. No UK institution writes at the $20m to $60m band these spinouts command, which is why a US chipmaker, not a UK fund, now sets the terms at the stage where ownership of the next decade's compute infrastructure is decided.

Deep Analysis

In plain English

When a startup needs money, it goes through rounds. The first rounds are small (seed, Series A) and the later ones are larger (Series B, C). Each round dilutes the founders and early investors a little: whoever puts in the money at each stage eventually owns a slice of the company. Orbital Industries, a London company, needed $50m for its Series B, its second big round. Plural, a European fund, led the round. Nvidia's investment arm (NVentures) joined alongside two US funds. None of the money came from a British fund or the UK government. That matters because the investors who write the largest cheques tend to own the largest slices. If Orbital is worth $1bn in five years, most of that profit goes to American and European balance sheets, not British ones. The UK grew the talent and hosts the company, but the financial upside of the growth stage sits elsewhere.

Deep Analysis
Root Causes

The UK capital stack for deeptech tops out structurally at the seed and Series A tier. The British Business Bank's expanded £6.6bn direct mandate (active April 2026) authorises cheques up to £60m, but as a development-bank cornerstone investor it targets fund structures and rarely leads a competitive growth round on its own balance sheet against US growth funds.

Plural, the only London-domiciled fund in Orbital's cap table, focuses on early European founders and leads at cheque sizes below the $20m threshold that characterises growth-stage competition.

The UK limited-partner base compounds the constraint. Domestic pension funds and insurance companies allocate a fraction of their assets to UK VC compared with US counterparts; the BVCA's 2024 LP survey found UK institutional investors supplied roughly 14% of capital raised by UK VC funds, against 55% in the US. Without that domestic LP depth, no UK fund can credibly raise a vehicle large enough to lead a $50m round.

What could happen next?
  • Consequence

    Equity upside from Orbital's growth stage accrues to NVentures, Radical Ventures and Compound rather than UK limited partners or sovereign vehicles.

    Long term · Assessed
  • Risk

    NVIDIA's strategic stake gives a US chipmaker direct visibility into a UK data-centre cooling supply chain, which it also competes in via its own cooling partnerships.

    Medium term · Assessed
  • Precedent

    A third consecutive ex-DeepMind mega-round with no UK lead confirms the pattern is structural rather than episodic, increasing pressure on the BBB's direct mandate to prove it can lead at growth stage.

    Short term · Reported
First Reported In

Update #6 · Orbital's $50m has no UK lead

Tech Funding News· 29 May 2026
Read original →
Causes and effects
This Event
Orbital's $50m raise has no UK lead
The third ex-DeepMind London mega-round in 18 months shows Britain growing world-class deeptech founders it cannot fund at Series B.
Different Perspectives
Abu Dhabi Investment Council
Abu Dhabi Investment Council
The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.
CDP Venture Capital
CDP Venture Capital
CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.
EDBI
EDBI
Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.
Forbion
Forbion
Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.
British Business Bank
British Business Bank
The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.
Stryker Corporation
Stryker Corporation
Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.